Diminished urinary prostacyclin metabolite in essential hypertension.
1. Urinary excretion rate of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), a stable nonenzymatic transformation product of prostacyclin (PGI2), was measured in 13 patients with sustained essential hypertension and in nine normotensive control subjects by a specific radioimmunoassay. 2. Patients with essential hypertension had significantly lower 6-keto-PGF1 alpha excretion rates irrespective of their sex, but in both groups urinary 6-keto-PGF1 alpha was lower in females. 3. Sodium excretion was significantly correlated with urinary 6-keto-PGF1 alpha only in hypertensive subjects. There was also a positive correlation between 6-keto-PGF1 alpha and urine volume in control subjects and in hypertensive patients. 4. If diminished urinary 6-keto-PGF1 alpha reflects suppressed endogenous PGI2 production, a deficiency in this important vasodepressor substance in essential hypertension may contribute to the pathogenesis of this disease.
D000328:Adult; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011453:Prostaglandins / Q000378:metabolism*; D011460:Prostaglandins F / Q000652:urine*; D012737:Sex Factors; D012964:Sodium / Q000652:urine
D011453:Prostaglandins; D011460:Prostaglandins F; D012964:Sodium; D011464:Epoprostenol